- In April 2024, FDA approved lutetium Lu 177 dotatate treatment for pediatric patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors
- In August 2024, Siemens Healthineers agreed to acquire the radiopharmaceutical business of Novartis for €200 million
- In June 2024, AstraZeneca announced the completion of the acquisition of Fusion Pharmaceuticals Inc., marking major steps forward in investing in radiopharmaceutical drugs for cancer
- In April 2024, RLS Radiopharmacies, a US radio pharmacy network, partnered with Eckert & Ziegler to start the production of radiopharmaceuticals containing Gallium-68
